Publications by authors named "N C Klein"
Combining energy harvesting with energy storage systems in a single device could offer great advantages for continuous power supply in both indoor and outdoor electric applications. In this work, we demonstrate a photochargeable sodium-ion battery (PSIB) based on a photoactive cathode of two-dimensional crystals of MoSe. This photocathode enables spontaneous photodriven charging of a sodium-ion battery cathode under illumination and an increase in the reversible capacity to 29% at 600 mA g compared to that under dark conditions during galvanostatic cycling.
View Article and Find Full Text PDFArticle Synopsis
- The text discusses the impact of pneumococcal conjugate vaccines (PCVs), specifically PCV10 and PCV13, on invasive pneumococcal disease (IPD) globally, highlighting how these vaccines have reduced the prevalence of disease caused by vaccine-type serotypes after extensive use.
- It describes the methodology of data collection from various surveillance sites, which aimed to evaluate IPD cases that occurred five years after the vaccines were implemented, focusing on different age groups for analysis.
- Findings indicate significant differences in serotype distribution between PCV10 and PCV13 sites; notably, certain serotypes, such as 19A and serotype 3, were prevalent in specific age groups, signaling ongoing challenges in controlling
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.
Lancet Infect Dis
December 2024
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages.
Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%.
Background: The 2023-2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses co-circulated. Seasonal influenza vaccine strains were well-matched to these viruses.
Methods: Using health care encounters data from health systems in 8 states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023-April 2024.